|
James Christie joined the biopharmaceutical industry in 1980 and has worked with GSK Celltech and Centocor BV before joining Therapeutic Antibodies Inc in 1998. He was appointed to the Protherics’ Board in September 1999. He has management responsibility for manufacturing quality process development and technical support operations in Australia the UK and Salt Lake City. He is also a trustee of the Protherics pension scheme. Mr Christie played a major part in the negotiations with AstraZeneca leading to the licensing agreement in December 2005 and more recently in establishing the manufacturing operation for OncoGel after the MacroMed acquisition in January 2007. | 